The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen

[Display omitted] •Crude risk of HCC higher for IFN-free recipients than IFN-containing recipients.•IFN-free and IFN-containing recipients differ with respect to confounding factors.•Association between IFN-free therapy and HCC disappears after adjusting for baseline confounders.•At HCC diagnosis, n...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of hepatology 2018-04, Vol.68 (4), p.646-654
Hauptverfasser: Innes, Hamish, Barclay, Stephen T., Hayes, Peter C., Fraser, Andrew, Dillon, John F., Stanley, Adrian, Bathgate, Andy, McDonald, Scott A., Goldberg, David, Valerio, Heather, Fox, Ray, Kennedy, Nick, Bramley, Pete, Hutchinson, Sharon J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] •Crude risk of HCC higher for IFN-free recipients than IFN-containing recipients.•IFN-free and IFN-containing recipients differ with respect to confounding factors.•Association between IFN-free therapy and HCC disappears after adjusting for baseline confounders.•At HCC diagnosis, no differences in nodule size or nodule number were apparent by regimen. Previous studies have reported a high frequency of hepatocellular carcinoma (HCC) occurrence in patients with advanced liver disease, after receipt of interferon (IFN)-free therapy for hepatitis C virus (HCV) infection. Our objective was to verify and account for this phenomenon using data from the Scottish HCV clinical database. We identified HCC-naïve individuals with liver cirrhosis receiving a course of antiviral therapy in Scotland from 1997–2016 resulting in a sustained virologic response. Patients were followed-up from their treatment start date to the earliest of: date of death, date of HCC occurrence, or 31 January 2017. We used Cox regression to compare the risk of HCC occurrence according to treatment regimen after adjusting for relevant co-factors (including: demographic factors; baseline liver disease stage; comorbidities/health behaviours, virology, and previous treatment experience). HCC occurrence was ascertained through both the HCV clinical database and medical chart review. For our main analysis, treatment regimen was defined as IFN-free vs. IFN-containing. A total of 857 patients met the study criteria, of whom 31.7% received an IFN-free regimen. Individuals receiving IFN-free therapy were more likely to be: older; of white ethnicity, Child-Turcotte-Pugh B/C vs. Child-Turcotte-Pugh A; thrombocytopenic; non-genotype 3; and treatment experienced. HCC occurrence was observed in 46 individuals during follow-up. In univariate analysis, IFN-free therapy was associated with a significantly increased risk of HCC (HR: 2.48; p = 0.021). However, after multivariate adjustment for baseline factors, no significant risk attributable to IFN-free therapy persisted (aHR: 1.15, p = 0.744). These findings suggest that the higher incidence of HCC following sustained virologic response with IFN-free therapy relates to baseline risk factors/patient selection, and not the use of IFN-free therapy per se. We examined the risk of liver cancer in 857 patients with cirrhosis in Scotland who received hepatitis C antiviral therapy and achieved a cure. We compared the risk of first-time liver cancer in
ISSN:0168-8278
1600-0641
DOI:10.1016/j.jhep.2017.10.033